ArticleArchives of microbiology2025
Purification and characterization of an exopolysaccharide produced by Lactiplantibacillus plantarum YM-4-3 strain isolated from home-made Yunnan Tempeh.
Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In this study, we investigated the enhanced biosynthesis and bioactivity of the exopolysaccharide (EPS) produced by Lactiplantibacillus plantarum YM-4-3, a strain isolated from Yunnan traditional tempeh. Comparative analysis revealed that modified MRS medium (MMRS) significantly increased EPS production from 122.64 ± 1.78 mg/L to 322.47 ± 3.08 mg/L compared to standard MRS culture. Monosaccharide composition analysis demonstrated consistent constituent profiles between culture conditions, though marked differences in relative abundance ratios were observed. By measuring the in vitro and intracellular antioxidant activity of EPS, it was found that the concentration of EPS reached 400 mg/L, the scavenging capacities of EPS produced by MRS Medium and modified MRS Medium reached 11.8 and 12.1% (DPPH), 46.94% and 53.3% (superoxide anion), 18.4% and 22.1% (hydroxyl free radical), respectively. Furthermore, cell-based assays demonstrated that EPS inhibited the growth of HeLa, HCT116, and U2OS cancer cells in a dose-dependent manner after 48 h of treatment. Transcriptomic profiling identified key metabolic pathways associated with EPS biosynthesis, including differential regulation of genes in the pentose phosphate pathway (LPST _ C2661, LPST _ C1728, LPST _ C2936), and galactose metabolism (LPST _ C2851, LPST _ C1737, LPST _ C2855). These findings provide mechanistic insights into the enhanced EPS production under optimized conditions. This study highlights the potential of L. plantarum YM-4-3 EPS as a natural antioxidant and anti-tumor agent, indicating its broad application prospects in the functional food and pharmaceutical sectors.
Indexed as
Identifiers
41222700What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.